MYGN Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

SPRZEDAż 121401 min ago

@ $21.69

Wydano: 14 vas. 2024 @ 16:30

Zwrot: 10.42%

Poprzedni sygnał: vas. 13 - 16:30

Poprzedni sygnał: Kupno

Zwrot: -1.99 %

Live Chart Being Loaded With Signals

Commentary (8 geg. 2024 @ 23:00):

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally...

Stats
Dzisiejszy wolumen	2.52M
Średni wolumen	666 375
Kapitalizacja rynkowa	2.15B
EPS	$0 ( 2024-02-27 )
Następna data zysków	( $-0.100 ) 2024-06-06
Last Dividend	$1.750 ( 2009-07-01 )
Next Dividend	$0 ( N/A )
P/E	-7.53
ATR14	$0.0680 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-14	Muzzey Dale	Sell	940	Common Stock
2024-04-14	Verratti Mark	Sell	1 076	Common Stock
2024-04-06	Munk Natalie	Sell	581	Common Stock
2024-03-14	Leffler Scott J.	Buy	46 905	Common Stock
2024-03-25	Munk Natalie	Sell	363	Common Stock

INSIDER POWER
52.49
Last 96 transactions
Buy: 1 118 283 \| Sell: 407 342

Wolumen Korelacja

Długi: 0.16 (neutral)

Krótki: 0.96 (very strong)

Signal:(61.18) Expect same movement, but be aware

Myriad Genetics Inc Korelacja

10 Najbardziej pozytywne korelacje
AXGN	0.804

10 Najbardziej negatywne korelacje
PAAS	-0.841
OSMT	-0.815
GETVV	-0.809

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Myriad Genetics Inc Korelacja - Waluta/Towar

-0.93
( very strong negative )

-0.56
( weak negative )

-0.92
( very strong negative )

-0.54
( weak negative )

0.82
( strong )

Myriad Genetics Inc Finanse

Annual	2022
Przychody:	$678.40M
Zysk brutto:	$476.40M (70.22 %)
EPS:	$-1.390

FY	2022
Przychody:	$678.40M
Zysk brutto:	$476.40M (70.22 %)
EPS:	$-1.390

FY	2021
Przychody:	$690.60M
Zysk brutto:	$493.00M (71.39 %)
EPS:	$-0.350

FY	2020
Przychody:	$638.60M
Zysk brutto:	$452.50M (70.86 %)
EPS:	$-2.69

Financial Reports:

No articles found.

Myriad Genetics Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Myriad Genetics Inc Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$1.750	2009-06-15
Last Dividend	$1.750	2009-07-01
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$3.50	--
Avg. Dividend % Per Year	0.00%	--
Score	2.02	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-12)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

2.02

Pay Frequency

Monthly

Yearly Payout

Year	Amount	Yield
2009	$3.50	10.20%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.374	1.500	-7.47	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.239	1.200	-7.96	-9.55	[0 - 0.3]
returnOnEquityTTM	-0.350	1.500	-5.00	-7.49	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.268	0.800	8.66	6.93	[1 - 3]
quickRatioTTM	0.963	0.800	9.04	7.23	[0.8 - 2.5]
cashRatioTTM	0.363	1.500	9.09	10.00	[0.2 - 2]
debtRatioTTM	0.175	-1.500	7.08	-10.00	[0 - 0.6]
interestCoverageTTM	-93.79	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.782	2.00	-0.261	-0.521	[0 - 30]
freeCashFlowPerShareTTM	-1.692	2.00	-0.846	-1.692	[0 - 20]
debtEquityRatioTTM	0.295	-1.500	8.82	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.689	1.000	1.852	1.852	[0.2 - 0.8]
operatingProfitMarginTTM	-0.370	1.000	-9.41	-9.41	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.317	1.000	-2.87	-2.87	[0.2 - 2]
assetTurnoverTTM	0.639	0.800	9.07	7.26	[0.5 - 2]
Total Score				-0.0149

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-5.89	1.000	-0.696	0	[1 - 100]
returnOnEquityTTM	-0.350	2.50	-3.21	-7.49	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.692	2.00	-0.564	-1.692	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.782	2.00	-0.261	-0.521	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.314	1.500	-5.43	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.0870	1.000	-4.68	0	[0.1 - 0.5]
Total Score				-2.32

Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.